Jacobs Levy Equity Management, Inc Athenex, Inc. Transaction History

Jacobs Levy Equity Management, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $0.91 $823,676 - $1.83 Million	-2,008,968 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.79 - $1.59 $441,246 - $888,078	558,540 Added 38.51%	2,008,968 $1.67 Million
Q4 2021 Feb 14, 2022	BUY	$1.36 - $2.94 $1.03 Million - $2.22 Million	755,104 Added 108.6%	1,450,428 $1.97 Million
Q3 2021 Nov 15, 2021	BUY	$2.97 - $4.84 $384,478 - $626,557	129,454 Added 22.88%	695,324 $2.09 Million
Q2 2021 Aug 16, 2021	BUY	$3.71 - $5.13 $361,951 - $500,487	97,561 Added 20.83%	565,870 $2.61 Million
Q1 2021 May 17, 2021	BUY	$4.08 - $14.75 $1.15 Million - $4.15 Million	281,205 Added 150.29%	468,309 $2.01 Million
Q4 2020 Feb 16, 2021	BUY	$11.06 - $14.01 $2.07 Million - $2.62 Million	187,104 New	187,104 $2.07 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.